0001140215 false Q1 --12-31 P4Y 0001140215 2022-01-01 2022-03-31 0001140215 2022-05-11 0001140215 2022-03-31 0001140215 2021-12-31 0001140215 2021-01-01 2021-03-31 0001140215 us-gaap:CommonStockMember 2021-12-31 0001140215 us-gaap:PreferredStockMember 2021-12-31 0001140215 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001140215 us-gaap:RetainedEarningsMember 2021-12-31 0001140215 us-gaap:CommonStockMember 2020-12-31 0001140215 us-gaap:PreferredStockMember 2020-12-31 0001140215 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001140215 us-gaap:RetainedEarningsMember 2020-12-31 0001140215 2020-12-31 0001140215 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001140215 us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001140215 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001140215 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001140215 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001140215 us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0001140215 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001140215 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001140215 us-gaap:CommonStockMember 2022-03-31 0001140215 us-gaap:PreferredStockMember 2022-03-31 0001140215 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001140215 us-gaap:RetainedEarningsMember 2022-03-31 0001140215 us-gaap:CommonStockMember 2021-03-31 0001140215 us-gaap:PreferredStockMember 2021-03-31 0001140215 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001140215 us-gaap:RetainedEarningsMember 2021-03-31 0001140215 2021-03-31 0001140215 us-gaap:SubsequentEventMember REED:SecuredConvertibleNotesMember REED:InstitutionalInvestorsMember 2022-05-09 0001140215 us-gaap:SubsequentEventMember REED:SecuredConvertibleNotesMember REED:InstitutionalInvestorsMember 2022-05-08 2022-05-09 0001140215 REED:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-03-31 0001140215 REED:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-03-31 0001140215 REED:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-03-31 0001140215 REED:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-03-31 0001140215 REED:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001140215 REED:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001140215 REED:VendorOneMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-03-31 0001140215 REED:VendorOneMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-03-31 0001140215 REED:VendorTwoMember us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember 2021-01-01 2021-03-31 0001140215 REED:VendorOneMember us-gaap:AccountsPayableMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-03-31 0001140215 REED:VendorTwoMember us-gaap:AccountsPayableMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-03-31 0001140215 REED:NoVendorMember us-gaap:AccountsPayableMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-12-31 0001140215 us-gaap:WarrantMember 2022-01-01 2022-03-31 0001140215 us-gaap:WarrantMember 2021-01-01 2021-03-31 0001140215 us-gaap:StockOptionMember 2022-01-01 2022-03-31 0001140215 us-gaap:StockOptionMember 2021-01-01 2021-03-31 0001140215 REED:UnvestedRestrictedCommonStockMember 2022-01-01 2022-03-31 0001140215 REED:UnvestedRestrictedCommonStockMember 2021-01-01 2021-03-31 0001140215 REED:SeriesAConvertiblePreferredStockMember 2022-01-01 2022-03-31 0001140215 REED:SeriesAConvertiblePreferredStockMember 2021-01-01 2021-03-31 0001140215 REED:RightOfUseAssetsUnderOperatingLeasesMember 2022-03-31 0001140215 REED:RightOfUseAssetsUnderOperatingLeasesMember 2021-12-31 0001140215 REED:ComputerHardwareAndSoftwareMember 2022-03-31 0001140215 REED:ComputerHardwareAndSoftwareMember 2021-12-31 0001140215 us-gaap:MachineryAndEquipmentMember 2022-03-31 0001140215 us-gaap:MachineryAndEquipmentMember 2021-12-31 0001140215 REED:AlternaCapitalSolutionsMember 2022-03-31 0001140215 REED:AlternaCapitalSolutionsMember 2021-12-31 0001140215 REED:RosenthalAndRosenthalIncMember 2022-03-31 0001140215 REED:RosenthalAndRosenthalIncMember 2021-12-31 0001140215 REED:AlternaCapitalSolutionsMember 2022-03-27 2022-03-28 0001140215 REED:AlternaCapitalSolutionsMember 2022-03-28 0001140215 REED:AlternaCapitalSolutionsMember 2022-01-01 2022-03-31 0001140215 REED:FinancingAgreementMember REED:RosenthalAndRosenthalIncMember 2018-12-31 0001140215 REED:FinancingAgreementMember REED:RosenthalAndRosenthalIncMember 2018-01-01 2018-12-31 0001140215 srt:MinimumMember REED:FinancingAgreementMember REED:RosenthalAndRosenthalIncMember 2018-01-01 2018-12-31 0001140215 srt:MaximumMember REED:FinancingAgreementMember REED:RosenthalAndRosenthalIncMember 2018-01-01 2018-12-31 0001140215 REED:RosenthalAgreementMember 2021-03-10 2021-03-11 0001140215 REED:JohnJBelloMember 2022-03-31 0001140215 REED:JohnJBelloMember 2022-01-01 2022-03-31 0001140215 REED:SecuritiesPurchaseAgreementMember us-gaap:PrivatePlacementMember 2022-03-09 2022-03-10 0001140215 us-gaap:PrivatePlacementMember REED:SecuritiesPurchaseAgreementMember 2022-03-10 0001140215 us-gaap:PrivatePlacementMember REED:SecuritiesPurchaseAgreementMember REED:OfficersAndDirectorsMember 2022-03-10 0001140215 REED:SecuritiesPurchaseAgreementMember us-gaap:PrivatePlacementMember REED:OfficerAndDirectorsMember 2022-03-10 0001140215 REED:SecuritiesPurchaseAgreementMember us-gaap:PrivatePlacementMember REED:OfficerAndDirectorsMember 2022-03-09 2022-03-10 0001140215 REED:JohnJBelloAndNancyEBelloMember 2022-01-01 2022-01-31 0001140215 REED:JohnJBelloAndNancyEBelloMember srt:MinimumMember 2022-01-31 0001140215 us-gaap:RestrictedStockMember 2021-12-31 0001140215 us-gaap:RestrictedStockMember 2022-01-01 2022-03-31 0001140215 us-gaap:RestrictedStockMember 2022-03-31 0001140215 REED:NonEmployeeDirectorsMember 2021-01-25 2021-01-26 0001140215 REED:FiveNonEmployeeDirectorsMember us-gaap:RestrictedStockMember 2021-01-25 2021-01-26 0001140215 REED:FiveNonEmployeeDirectorsMember us-gaap:RestrictedStockMember REED:FebruaryOneTwoThousandTwentyOneMember 2021-01-25 2021-01-26 0001140215 REED:FiveNonEmployeeDirectorsMember us-gaap:RestrictedStockMember REED:MayOneTwoThousandTwentyTwoAugustOneTwoThousandTwentyTwoAndNovemberOneTwoThousandTwentyTwoMember 2021-01-26 0001140215 REED:FiveNonEmployeeDirectorsMember us-gaap:RestrictedStockMember 2021-01-26 0001140215 us-gaap:RestrictedStockMember 2021-01-01 2021-03-31 0001140215 REED:TwoThousandTwentyIncentiveCompensationPlanMember 2022-03-31 0001140215 REED:EmployeesMember 2022-01-01 2022-03-31 0001140215 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001140215 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001140215 us-gaap:EmployeeStockOptionMember 2022-03-31 0001140215 us-gaap:StockOptionMember 2021-12-31 0001140215 us-gaap:StockOptionMember 2022-01-01 2022-03-31 0001140215 us-gaap:StockOptionMember 2022-03-31 0001140215 REED:StockWarrantsMember 2022-03-31 0001140215 REED:SatisfactionSettlementAndReleaseAgreementMember REED:JohnBelloMember 2021-11-24 0001140215 2021-11-23 2021-11-24 0001140215 REED:SatisfactionSettlementAndReleaseAgreementMember REED:JohnBelloMember 2021-12-31 0001140215 REED:SatisfactionSettlementAndReleaseAgreementMember REED:JohnBelloMember 2022-01-01 2022-03-31 0001140215 us-gaap:WarrantMember 2021-12-31 0001140215 us-gaap:WarrantMember 2022-03-31 0001140215 REED:ChrisReedMember REED:CaliforniaCustomBeverageLLCMember 2018-12-31 0001140215 REED:ChrisReedMember REED:CaliforniaCustomBeverageLLCMember 2022-03-31 0001140215 REED:ChrisReedMember REED:CaliforniaCustomBeverageLLCMember 2022-01-01 2022-03-31 0001140215 REED:ChrisReedMember REED:CaliforniaCustomBeverageLLCMember 2019-12-31 0001140215 us-gaap:RoyaltyMember REED:CaliforniaCustomBeverageLLCMember 2022-01-01 2022-03-31 0001140215 us-gaap:RoyaltyMember REED:CaliforniaCustomBeverageLLCMember 2021-01-01 2021-03-31 0001140215 REED:ChrisReedMember REED:CaliforniaCustomBeverageLLCMember 2021-12-31 0001140215 us-gaap:RoyaltyMember 2022-01-01 2022-03-31 0001140215 REED:LindsayMartinMember srt:VicePresidentMember 2022-01-01 2022-03-31 0001140215 REED:LindsayMartinMember srt:VicePresidentMember 2021-01-01 2021-03-31 0001140215 us-gaap:SubsequentEventMember 2022-04-01 2022-05-16 0001140215 us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember REED:NotePurchaseAgreementMember 2022-05-09 0001140215 us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember REED:NotePurchaseAgreementMember 2022-05-08 2022-05-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure REED:Segment

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2022

 

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934

 

For the transition period from _______ to _______

 

Commission file number: 001-32501

 

REED’S, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   35-2177773

(State of

incorporation)

  

(I.R.S. Employer

Identification No.)

 

201 Merritt 7, Norwalk, CT. 06851

(Address of principal executive offices) (Zip Code)

 

(800) 997-3337

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol   Names of each exchange on which registered
Common Stock   REED   NASDAQ

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: There were a total of 112,652,320 shares of Common Stock outstanding as of May 11, 2022.

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:

 

Large Accelerated Filer ☐ Accelerated Filer ☐ Non-Accelerated Filer ☒
Smaller Reporting Company ☒ Emerging Growth Company ☐  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the issuer is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

 

 

 

 

 

TABLE OF CONTENTS

 

PART I - FINANCIAL INFORMATION F-1
   
Item 1. Condensed Financial Statements F-1
   
Condensed Balance Sheets - March 31, 2022 (Unaudited) and December 31, 2021 F-1
   
Condensed Statements of Operations for the three months ended March 31, 2022 and 2021(Unaudited) F-2
   
Condensed Statements of Changes in Stockholders’ Equity (Deficit) for the three months ended March 31, 2022 and 2021(Unaudited) F-3
   
Condensed Statements of Cash Flows for the three months ended March 31, 2022 and 2021 (Unaudited) F-4
   
Notes to Condensed Financial Statements three months ended March 31, 2022 and 2021 (Unaudited) F-5
   
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 1
   
Item 3. Quantitative and Qualitative Disclosures About Market Risk 6
   
Item 4. Controls and Procedures 6
   
PART II – OTHER INFORMATION 7
   
Item 1. Legal Proceedings 7
   
Item 1A. Risk Factors 7
   
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 7
   
Item 3. Defaults Upon Senior Securities 7
   
Item 4. Mine Safety Disclosures 7
   
Item 5. Other Information 7
   
Item 6. Exhibits 8

 

i

 

 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS AND INFORMATION

 

This Quarterly Report on Form 10-Q as well as our other public filings or public statements include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by terms and phrases such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “should,” and “will” and similar expressions and include references to assumptions and relate to our future prospects, developments, and business strategies.

 

These forward-looking statements involve known and unknown risks, assumptions and uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by forward-looking statements. These risks, assumptions and uncertainties include difficulty in marketing Reed’s products and services, maintaining and protecting brand recognition, the need for significant capital, our significant debt obligations, dependence on third party distributors, dependence on third party brewers, increasing costs of fuel and freight, protection of intellectual property, competition and other factors, any of which could have an adverse effect on the business plans of Reed’s, its reputation in the industry or its expected financial return from operations and results of operations. These risks, assumptions and uncertainties are not necessarily all of the important factors that could cause actual results to differ materially from those expressed in any of our forward-looking statements.

 

We undertake no obligation to update or revise the forward-looking statements included in this report, whether as a result of new information, future events or otherwise, after the date of this report. Our actual results, performance or achievements could differ materially from the results expressed in, or implied by, these forward-looking statements.

 

ii
 

 

Part I – FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

REED’S, INC,

CONDENSED BALANCE SHEETS

(Amounts in thousands, except share amounts)

 

  

March 31, 2022

   December 31, 2021 
   (Unaudited)     
ASSETS          
Current assets:          
Cash  $122   $49 
Accounts receivable, net of allowance of $277 and $234, respectively   5,161    5,183 
Inventory   20,848    17,049 
Receivable from related party   1,135    933 
Prepaid expenses and other current assets   1,561    1,491 
Total current assets   28,827    24,705 
           
Property and equipment, net of accumulated depreciation of $613 and $561, respectively   940    992 
Intangible assets   624    624 
Total assets  $30,391   $26,321 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities:          
Accounts payable  $16,359   $10,434 
Accrued expenses   689    286 
Revolving line of credit, net of capitalized financing costs of $470 and $0, respectively   7,475    10,229 
Payable to related party   735    614 
Current portion of lease liabilities   167    161 
Total current liabilities   25,425    21,724 
           
Lease liabilities, less current portion   350    394 
Total liabilities   25,775    22,118 
           
Stockholders’ equity:          
Series A Convertible Preferred stock, $10 par value, 500,000 shares authorized, 9,411 shares issued and outstanding   94    94 
Common stock, $.0001 par value, 180,000,000 shares authorized; 112,551,890 and 93,733,975 shares issued and outstanding, respectively   11    9 
Additional paid in capital   112,628    107,237 
Accumulated deficit   (108,117)   (103,137)
Total stockholders’ equity   4,616    4,203 
Total liabilities and stockholders’ equity  $30,391   $26,321 

 

The accompanying notes are an integral part of these condensed financial statements.

 

F-1

 

 

REED’S, INC.

CONDENSED STATEMENTS OF OPERATIONS

For the Three Months Ended March 31, 2022 and 2021

(Unaudited)

(Amounts in thousands, except share and per share amounts)

 

  

March 31, 2022

  

March 31, 2021

 
Net Sales  $12,182   $12,146 
Cost of goods sold   9,250    8,293 
Gross profit   2,932    3,853 
           
Operating expenses:          
Delivery and handling expense   2,812    3,286 
Selling and marketing expense   2,178    2,215 
General and administrative expense   2,121    2,603 
Total operating expenses   7,111    8,104 
           
Loss from operations   (4,179)   (4,251)
           
Other income (expense)   -    - 
Interest expense   (801)   (256)
           
Net loss  $(4,980)  $(4,507)
           
Net loss per share – basic and diluted  $(0.05)  $(0.05)
           
Weighted average number of shares outstanding – basic and diluted   97,377,408    86,631,304 

 

The accompanying notes are an integral part of these condensed financial statements.

 

F-2

 

 

REED’S, INC.

CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

For the Three Months Ended March 31, 2022 and 2021

(Unaudited)

(Amounts in thousands except share amounts)

 

                             
   Common Stock   Preferred Stock   Additional Paid In   Accumulated   Total Stockholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
Balance, December 31, 2021   93,733,975   $9    9,411   $94   $107,237   $(103,137)  $4,203 
Fair value of vested options                       225         225 
Fair value of vested restricted shares granted to officers   136,594         -         66         66 
Repurchase of common stock   (13,250)                  (2)        (2)
Common shares issued for financing costs   100,000         -         37         37 
Common shares issued for cash, net of offering costs   18,594,571    2              5,065         5,067 
Net loss   -    -    -    -    -    (4,980)   (4,980)
Balance, March 31, 2022   112,551,890   $11    9,411   $94   $112,628   $(108,117)  $4,616 

 

   Common Stock   Preferred Stock   Additional Paid In   Accumulated   Total Stockholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
Balance, December 31, 2020   86,317,096   $9    9,411   $94   $97,031   $(86,730)  $10,404 
Fair value of vested options                       300         300 
Fair value of vested restricted shares granted to officers   84,809         -         98         98 
Common shares issued on exercise of options   6,000                   3         3 
Common shares issued for financing costs   400,000         -         472         472 
Net loss   -    -    -    -    -    (4,507)   (4,507)
Balance, March 31, 2021   86,807,905   $9    9,411   $94   $97,904   $(91,237)  $6,770 

 

The accompanying notes are an integral part of these condensed financial statements.

 

F-3

 

 

REED’S, INC.

CONDENSED STATEMENTS OF CASH FLOWS

For the Three Months Ended March 31, 2022 and 2021

(Unaudited)

(Amounts in thousands)

 

   March 31, 2022   March 31, 2021 
Cash flows from operating activities:          
Net loss  $(4,980)  $(4,507)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation   25    32 
Amortization of debt discount   65    162 
Amortization of prepaid financing costs   431    25 
Fair value of vested options   225    292 
Fair value of vested restricted shares granted to officers   66    106 
Fair value of common shares issued as financing costs   37      
Change in allowance for doubtful accounts   62    (69)
Inventory write-downs   10    (20)
Gain on termination of leases   -    (3)
Changes in operating assets and liabilities:          
Accounts receivable   (40)   (244)
Inventory   (3,810)   (1,306)
Prepaid expenses and other assets   (617)   (484)
Decrease in right of use assets   27    24 
Accounts payable   5,926    1,387 
Accrued expenses   403    (446)
Lease liability   (37)   (8)
Net cash used in operating activities   (2,207)   (5,059)
Cash flows from investing activities:          
Patent costs   -    (2)
Purchase of property and equipment   -    (95)
Net cash used in investing activities   -    (97)
Cash flows from financing activities:          
Proceeds from line of credit   14,508    16,154 
Payments on line of credit   (17,212)   (11,898)
Proceeds from sale of common stock   5,067    - 
Repurchase of common stock   (2)   - 
Amounts from related party, net   (81)   459 
Payments on capital lease obligation   -    (2)
Proceeds from exercise of options   -    3 
Net cash provided by financing activities   2,280    4,716 
           
Net increase (decrease) in cash   73    (440)
Cash at beginning of period   49    595 
Cash at end of period  $122   $155 
           
Supplemental disclosures of cash flow information:          
Cash paid for interest  $256   $70 

 

The accompanying notes are an integral part of these condensed financial statements.

 

F-4

 

 

REED’S, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

Three Months Ended March 31, 2022 and 2021 (Unaudited)

(In thousands, except share and per share amounts)

 

1. Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying condensed financial statements of Reed’s, Inc. (the “Company”, “we”, “us”, or “our”), have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. We believe that the disclosures contained in these condensed financial statements are adequate to make the information presented herein not misleading. These condensed financial statements should be read in conjunction with the financial statements contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on April 15, 2022. The accompanying condensed financial statements are unaudited, but in the opinion of management contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company’s financial position as of March 31, 2022, and the results of its operations and its cash flows for the three months ended March 31, 2022 and 2021. The balance sheet as of December 31, 2021 is derived from the Company’s audited financial statements.

 

The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results of operations to be expected for the full fiscal year ending December 31, 2022.

 

Going Concern

 

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying financial statements, for the three months ended March 31, 2022, the Company recorded a net loss of $4,980 and used cash in operations of $2,207. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s December 31, 2021, financial statements, raised substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

 

As of March 31, 2022, we had a cash balance of $122, with no current availability, and $5,100 of additional borrowing capacity, stockholders’ equity of $4,616 and a working capital of $3,402.

 

On May 9, 2022 the Company issued $11,250 of secured convertible notes to certain institutional investors. The convertible notes mature May 9, 2025, bear interest at 10% per annum, and are secured by substantially all of the Company’s assets. The initial conversion rate of the convertible notes is 4.1503 shares of the Company’s common stock per one dollar of principal amount converted (See Note 11).

 

Historically, we have financed our operations through public and private sales of common stock, issuance of preferred and common stock, convertible debt instruments, term loans and credit lines from financial institutions, and cash generated from operations. To alleviate these conditions, management is currently evaluating various funding alternatives and may seek to raise additional funds through the issuance of equity, mezzanine or debt securities, through arrangements with strategic partners or through obtaining credit from financial institutions. As we seek additional sources of financing, there can be no assurance that such financing would be available to us on favorable terms or at all. Our ability to obtain additional financing in the debt and equity capital markets is subject to several factors, including market and economic conditions, our performance and investor sentiment with respect to us and our industry.

 

We have also taken decisive action to improve our margins, including fully outsourcing our manufacturing process, streamlining our product portfolio, negotiating improved vendor contracts and restructuring our selling prices.

 

F-5

 

 

During the first quarter of 2022, the Company continued to strengthen its supply chain, implement gross margin enhancement initiatives, drive efficiencies in transportation and warehouse costs and reduce operating expenses.

 

The Company remains focused on driving sales growth and improving margin. The sales growth focus is on channel expansion, new product introduction and improved sales execution. The margin enhancement initiative is driven by co-packer upgrades, better leveraged purchasing and improved efficiency. Underpinning these initiatives is a focus on strategically reducing operating costs, particularly delivery and handling expenses. During 2021, the Company experienced elevated transportation costs over the prior year and anticipates these costs to remain elevated for the balance of 2022. Plans have been implemented to mitigate the impact of these costs.

 

COVID-19 Considerations

 

During the period ended March 31, 2022, the COVID-19 pandemic continued to impact our operating results and the Company anticipates a residual effect for the balance of the year. In addition, the pandemic could cause reduced demand for our products if, for example, the pandemic results in a recessionary economic environment which negatively effects the consumers who purchase our products. Based on the recent increase in demand for our products, we believe that over the long term, there will continue to be strong demand for our products.

 

Through March 31, 2022, the Company was able to lower its freight costs despite a higher transportation market as the capacity in the freight market has not kept up with demand. The Company believes these challenges will continue throughout the year. In addition, the Company experienced increases in the pricing of several of its raw materials and delays in procuring several of these items. However, mitigation plans have been implemented to manage this risk. Additionally, the Company was negatively impacted by supply chain challenges impacting our ability to benefit from strong demand for, and increased sales of our product. The disruption caused by labor shortages, significant raw material cost inflation, logistics issues and increased freight costs, and ongoing port congestion, resulted in suppressed margins and net income. The Company anticipates a continued impact throughout 2022.

 

Our ability to operate without significant incremental negative operational impact from the COVID-19 pandemic will in part depend on our ability to protect our employees and protect our supply chain. The Company has endeavored to follow the recommended actions of government and health authorities to protect our employees. Since the inception of the COVID-19 pandemic and through March 31, 2022, we maintained the consistency of our operations during the onset of the COVID-19 pandemic. We will continue to innovate in managing our business, coordinating with our employees and suppliers to do our part in the infection prevention and remain flexible in responding to our customers and suppliers. However, the uncertainty resulting from the pandemic could result in an unforeseen disruption to our workforce and supply chain (for example an inability of a key supplier or transportation supplier to source and transport materials) that could negatively impact our operations.

 

F-6

 

 

We have not observed any material impairments of our assets or a significant change in the fair value of our assets due to the COVID-19 pandemic.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Those estimates and assumptions include estimates for reserves of uncollectible accounts, inventory obsolescence, depreciable lives of property and equipment, analysis of impairments of recorded long-term tangible and intangible assets, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services.

 

Revenue Recognition

 

The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers (“ASC 606”). Revenue and costs of sales are recognized when control of the products transfers to our customer, which generally occurs upon shipment from our facilities. The Company’s performance obligations are satisfied at that time. The Company does not have any significant contracts with customers requiring performance beyond delivery, and contracts with customers contain no incentives or discounts that could cause revenue to be allocated or adjusted over time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfilment activity rather than a promised service to the customer. All of the Company’s products are offered for sale as finished goods only, and there are no performance obligations required post-shipment for customers to derive the expected value from them.

 

The Company does not allow for returns, except for damaged products when the damage occurred pre-fulfilment. Damaged product returns have historically been insignificant. Because of this, the stand-alone nature of our products, and our assessment of performance obligations and transaction pricing for our sales contracts, we do not currently maintain a contract asset or liability balance for obligations. We assess our contracts and the reasonableness of our conclusions on a quarterly basis.

 

F-7

 

 

Loss per Common Share

 

Basic earnings (loss) per share is computed by dividing the net income (loss) applicable to common stockholders by the weighted average number of shares of common stock outstanding during the year, excluding shares of unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted earnings (loss) per share is computed by dividing the net income applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted. Potential common shares are excluded from the computation when their effect is antidilutive.

 

For the periods ended March 31, 2022 and 2021, the calculations of basic and diluted loss per share are the same because potential dilutive securities would have had an anti-dilutive effect. The potentially dilutive securities consisted of the following:

 

  

March 31,

2022

  

March 31,

2021

 
Warrants   

13,835,768

    3,362,241 
Options   10,145,176    11,028,322 
Unvested restricted common stock   376,290    309,082 
Series A Convertible Preferred stock   37,644    37,644 
Total   

24,394,878

    14,737,289 

 

Stock Compensation Expense

 

The Company periodically issues stock options and restricted stock awards to employees and non-employees in non-capital raising transactions for services and for financing costs. The Company accounts for such grants issued and vesting based on ASC 718, Compensation-Stock Compensation whereby the value of the award is measured on the date of grant and recognized for employees as compensation expense on the straight-line basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. The Company recognizes the fair value of stock-based compensation within its Statements of Operations with classification depending on the nature of the services rendered.

 

The fair value of the Company’s stock options is estimated using the Black-Scholes-Merton Option Pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the stock options or restricted stock, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes-Merton Option Pricing model and based on actual experience. The assumptions used in the Black-Scholes-Merton Option Pricing model could materially affect compensation expense recorded in future periods.

 

Advertising Costs

 

Advertising costs are expensed as incurred and are included in selling and marketing expense. Advertising costs aggregated $312 and $349 for the three months ended March 31, 2022 and 2021, respectively.

 

Concentrations

 

Net sales. During the three months ended March 31, 2022, the Company’s two largest customers accounted for 18% and 12% of net sales, respectively. During the three months ended March 31, 2021, the Company’s two largest customers accounted for 23% and 12% of net sales, respectively. No other customers exceeded 10% of net sales in either period.

 

Accounts receivable. As of March 31, 2022, the Company had accounts receivable from one customer which comprised 23% of its gross accounts receivable. As of December 31, 2021, the Company had accounts receivable from one customer which comprised 18% of its gross accounts receivable. No other customers exceeded 10% of gross accounts receivable in either period.

 

F-8

 

 

Purchases from vendors. During the three months ended March 31, 2022, the Company’s largest vendor accounted for approximately 13% of all purchases. During the three months ended March 31, 2021, the Company’s two largest vendor accounted for approximately 13% and 13% of all purchases, respectively. No other vendors exceeded 10% of all purchases in either period.

 

Accounts payable. As of March 31, 2022, the Company’s two largest vendors accounted for 11% and 10% of the total accounts payable, respectively. As of December 31, 2021, no vendor accounted for more than 10% the total accounts payable. No other vendors exceeded 10% of gross accounts payable in either period.

 

Fair Value of Financial Instruments

 

The Company uses various inputs in determining the fair value of its financial assets and liabilities and measures these assets on a recurring basis. Financial assets recorded at fair value are categorized by the level of subjectivity associated with the inputs used to measure their fair value. ASC 820 defines the following levels of subjectivity associated with the inputs:

 

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.

Level 3—Unobservable inputs based on the Company’s assumptions.

 

The carrying amounts of financial assets and liabilities, such as cash and cash equivalents, accounts receivable, short-term bank loans, accounts payable, notes payable and other payables, approximate their fair values because of the short maturity of these instruments. The carrying values of capital lease obligations and long-term financing obligations approximate their fair values because interest rates on these obligations are based on prevailing market interest rates.

 

Recent Accounting Pronouncements

 

Recently Adopted Accounting Pronouncements

 

In August 2020, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2020-06 “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”).” ASU 2020-06 reduces the number of accounting models for convertible debt instruments by eliminating the cash conversion and beneficial conversion models. The diluted net income per share calculation for convertible instruments will require the Company to use the if-converted method. For contracts in an entity’s own equity, the type of contracts primarily affected by this update are freestanding and embedded features that are accounted for as derivatives under the current guidance due to a failure to meet the settlement conditions of the derivative scope exception. This update simplifies the related settlement assessment by removing the requirements to (i) consider whether the contract would be settled in registered shares, (ii) consider whether collateral is required to be posted, and (iii) assess shareholder rights. ASU 2020-06 is effective January 1, 2024, for the Company and the provisions of this update can be adopted using either the modified retrospective method or a fully retrospective method. Early adoption is permitted, but no earlier than January 1, 2021, including interim periods within that year. Effective January 1, 2021, the Company early adopted ASU 2020-06 and that adoption did not have an impact on our financial statements and related disclosures.

 

In May 2021, the FASB issued ASU 2021-04 “Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation— Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815- 40) Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options” (“ASU 2021-04”). ASU 2021-04 provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective date. The Company adopted ASU 2021-04 effective January 1, 2022. The adoption of ASU 2021-04 did not have any impact on the Company’s financial statement presentation or disclosures.

 

F-9

 

 

Recently Issued Accounting Pronouncements Not Yet Adopted

 

In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning January 1, 2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related codification improvements will be material to its financial position, results of operations and cash flows.

 

Other recent accounting pronouncements issued by the FASB, its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

 

2. Inventory

 

Inventory is valued at the lower of cost (first-in, first-out) or net realizable value, net of write downs, and is comprised of the following (in thousands):

 

  

March 31,

2022

  

December 31,

2021

 
Raw materials and packaging  $11,853   $11,221 
Finished products   8,995    5,828 
Total  $20,848   $17,049 

 

3. Property and Equipment

 

Property and equipment is comprised of the following (in thousands):

 

  

March 31,

2022

  

December 31,

2021

 
Right-of-use assets under operating leases  $724   $724 
Computer hardware and software   400    400 
Machinery and equipment   429    429 
Total cost   1,553    1,553 
Accumulated depreciation and amortization   (613)   (561)
Net book value  $940   $992 

 

Depreciation expense for the three months ended March 31, 2022 and 2021 was $25 and $32, respectively, and amortization of right-of-use assets for the three months ended March 31, 2022 and 2021 was $27 and $24, respectively.

 

4. Intangible Assets

 

Intangible assets consist of the following (in thousands):

 

  

March 31,

2022

  

December 31,

2021

 
Brand names  $576   $576 
Trademarks   48    48 
Total  $624   $624 

 

F-10

 

 

5. Line of Credit

 

Amounts outstanding under the Company’s credit facilities are as follows (in thousands):

 

  

March 31,

2022

  

December 31,

2021

 
Line of credit – Alterna Capital Solutions  $7,945   $- 
Line of credit – Rosenthal & Rosenthal   -    10,229 
Capitalized financing costs   (470)   - 
Total  $7,475   $10,229 

 

Alterna Capital Solutions

 

On March 28, 2022, the Company entered into a financing agreement with Alterna Capital Solutions (“ACS”), for a line of credit to replace its existing credit facility. The ACS line of credit is for a term of 3 years, provides for borrowings of up to $13,000, and is secured by eligible accounts receivable and inventory. An over advance rider provides for up to $400 of additional borrowing beyond those amounts (the “Over Advance”). At March 31, 2022, no unused borrowing capacity was available under the financing agreement.

 

Borrowings based on receivables bears an interest of prime plus 4.75% but not less than 8.0%. Borrowings based on inventory bears an interest of prime plus 5.25% but not less than 8.5%. The additional over advance rider bears a rate of prime plus 12.75%, but not less than 16.00%. Additionally, the line of credit is subject to monthly monitoring fee of $1 with a minimum usage requirement on the credit facility. A loan balance of less than $1,500 will bear interest at a rate in line with account receivables advances plus the monthly monitoring fee of $1.

 

The Company incurred $503 of direct costs of the transaction, consisting primarily of broker, bank and legal fees. These costs have been capitalized and are being amortized over the 3-year life of the ACS agreement. For the three months ended March 31, 2022, amortization of debt discount was $33, and as of March 31, 2022, the remaining unamortized debt discount balance is $470.

 

Rosenthal & Rosenthal (paid off in full on March 30, 2022)

 

In 2018, the Company entered into a financing agreement with Rosenthal & Rosenthal, Inc. (“Rosenthal”) that provided a maximum borrowing capacity of $13,000, based on eligible accounts receivable and inventories (the “permitted borrowings”) plus advances (an “over-advance” of up to $4,000) in excess of permitted borrowings. On March 30, 2022, the Company paid in full the outstanding balance on its credit facility with Rosenthal with proceeds from ACS discussed above.

 

Borrowings under the Rosenthal financing agreement bore interest at the greater of prime or 4.75%, plus an additional 2.0% to 3.5% depending on whether the borrowing was based upon receivables, inventory or is an over-advance. Additionally, the Rosenthal line of credit was subject to monthly facility and administration fees, and aggregate minimum monthly fees (including interest) of $4.

 

The line of credit was secured by substantially all of the assets, excluding intellectual property, of the Company. The over-advance was secured by all of Reed’s intellectual property collateral. On March 11, 2021, the Company entered into an amendment to the Rosenthal agreement and replaced a standby letter of credit of $1,500 by a guarantor with a $2,000 pledge of securities to Rosenthal by John J. Bello and Nancy E. Bello, as Co-Trustees of The John and Nancy Bello Revocable Living Trust. John J. Bello, current Chairman and former Interim Chief Executive Officer of Reed’s, is a related party, and greater than 5% beneficial owner of Reed’s common stock. As consideration for the collateral support, Mr. Bello received 400,000 shares of Reed’s restricted stock, with a fair value of $472 which was recorded a prepaid financing cost. During the three months ended March 31, 2022, $121 of the prepaid financing cost was amortized, and as of March 31, 2022, there was no remaining unamortized prepaid finance cost balance.

 

The Company annually incurs an additional $130 of fees from the bank, which is equal to 1% of the $13,000 borrowing limit. Amortization of this debt discount was $65 and $162 for the three months ended March 31, 2022, and 2021, respectively. At March 31, 2022, there was no remaining unamortized debt discount balance.

 

F-11

 

 

6. Leases Liabilities

 

During the three months ended March 31, 2022 and 2021, lease costs totaled $27 and $24, respectively.

 

As of December 31, 2021, operating lease liabilities totaled $555. During the three months ended March 31, 2022, the Company made payments of $38 towards its operating lease liability. As of March 31, 2022, operating lease liabilities totaled $518.

 

As of March 31, 2022, the weighted average remaining lease terms for an operating lease are 2.76 years. As of March 31, 2022, the weighted average discount rate on the operating lease is 12.60%.

 

7. Stockholder’s Equity

 

On March 10, 2022, the Company entered into a securities purchase agreement with certain institutional and accredited investors pursuant to which the investors agreed to purchase 18,594,571 shares of the Company’s common stock and warrants to purchase 9,297,289 shares of common stock in a private placement (including 3,248,142 shares of the Company’s common stock and warrants to purchase 1,624,071 shares of common stock to investors who are officers and directors of the Company). The warrants have an exercise price of $0.2877 per share for a period of five years commencing six months from the closing date of March 11, 2022. The purchase price per share of common stock and associated warrant was $0.28 for certain investors and was $0.3502 for investors who are officers and directors of the Company in compliance with the rules of the Nasdaq Stock Market. The net proceeds to the Company, after deducting placement agent fees and other offering expenses, was approximately $5.1 million. The officers and directors of the Company purchased approximately $1.1 million of the securities in the offering.

  

In January 2022, the Company issued 100,000 shares of common stock valued at $37 to John J. Bello and Nancy E. Bello, as Co-Trustees of The John and Nancy Bello Revocable Living Trust as consideration for the $2,000 pledge of securities to Rosenthal (see Note 5). John J. Bello, current Chairman and former Interim Chief Executive Officer of Reed’s, is a related party, and greater than 5% beneficial owner of Reed’s common stock.

 

8. Stock-Based Compensation

 

Restricted common stock

 

The following table summarizes restricted stock activity during the three months ended March 31, 2022:

 

   Unvested
Shares		   Issuable
Shares		   Fair Value
at Date of
Issuance		   Weighted
Average
Grant Date
Fair Value		 
Balance, December 31, 2021   111,164    -   $54    0.89 
Granted   401,720    -    150    0.37 
Vested   (136,594)   136,594    -    - 
Forfeited   -              - 
Issued   -    (136,594)   (66)   - 
Balance, March 31, 2022   376,290    -   $138   $0.51 

 

On January 26, 2022, the board of directors of Reed’s, pursuant to a joint recommendation from its governance and compensation committees, set the cash compensation of its non-employee directors at $50,000 for fiscal 2021, payable quarterly in accordance with the company’s policies for non-employee director compensation. In addition, the Company granted 401,720 restricted stock awards to five non-employee directors. 100,430 of these restricted stock awards vested on February1, 2022. The remaining 301,290 restricted stock awards will vest equally on May 1, 2022, August 1, 2022, and November 1, 2022. The aggregate fair value of the stock awards was $150 based on the market price of our common stock price which was $0.32 per share on the date of grants and is amortized as shares vest.

 

The total fair value of restricted common stock vesting during the three months ended March 31, 2022 and 2021, was $66 and $98, respectively, and is included in general and administrative expenses in the accompanying statements of operations. As of March 31, 2022, the amount of unvested compensation related to issuances of restricted common stock was $138, which will be recognized as an expense in future periods as the shares vest. When calculating basic loss per share, these shares are included in weighted average common shares outstanding from the time they vest. When calculating diluted net income per share, these shares are included in weighted average common shares outstanding as of their grant date.

 

F-12

 

 

Stock options

 

The following table summarizes stock option activity during the three months ended March 31, 2022:

 

   Shares   Weighted-
Average
Exercise Price		   Weighted-
Average
Remaining
Contractual
Terms
(Years)		   Aggregate
Intrinsic
Value		 
Outstanding at December 31, 2021   10,522,995   $1.12    7.88   $- 
Granted   60,000   $0.29           
Exercised   -   $-           
Unvested forfeited   (236,818)  $1.81           
Vested forfeited   (201,001)  $1.61                  
Outstanding at March 31, 2022   10,145,176   $1.09    7.82   $- 
Exercisable at March 31, 2022   4,784,540   $1.18    7.00   $- 

 

During the three months ended March 31, 2022, the Company approved options exercisable into 60,000 shares to be issued pursuant to Reed’s 2020 Equity Incentive Plan. 60,000 options were issued to employees, 30,000 options vesting annually over a four-year vesting period, and 30,000 options vesting based on performance criteria to be established by the board of directors.

 

The stock options are exercisable at a price of $0.29 per share and expire in ten years. The total fair value of these options at grant date was approximately $12, which was determined using a Black-Scholes-Merton option pricing model with the following average assumption: stock price of $0.29 share, expected term of six years, volatility of 82%, dividend rate of 0%, and weighted average risk-free interest rate of 1.72%. The expected term represents the weighted-average period of time that share option awards granted are expected to be outstanding giving consideration to vesting schedules and historical participant exercise behavior; the expected volatility is based upon historical volatility of the Company’s common stock; the expected dividend yield is based on the fact that the Company has not paid dividends in the past and does not expect to pay dividends in the future; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of measurement corresponding with the expected term of the share option award.

 

During the three months ended March 31, 2022 and 2021, the Company recognized $225 and $300 of compensation expense relating to vested stock options. As of March 31, 2022, the aggregate amount of unvested compensation related to stock options was approximately $2,398 which will be recognized as an expense as the options vest in future periods through March 28, 2026.

 

As of March 31, 2022, the outstanding and exercisable options have no intrinsic value. The aggregate intrinsic value was calculated as the difference between the closing market price as of March 31, 2022, which was $0.30, and the exercise price of the outstanding stock options.

 

9. Stock Warrants

 

As of March 31, 2022, the Company has issued warrants to purchase an aggregate of 13,835,768 shares of common stock. The Company’s warrant activity during the three months ended March 31, 2022 is as follows:

   Shares  

Weighted-

Average Exercise Price

  

Weighted-

Average Remaining Contractual Terms (Years)

   Aggregate Intrinsic Value 
                 
Outstanding at December 31, 2021   4,538,479   $1.02    2.77   $- 
Granted   9,297,289    0.29    5.45      
Exercised   -    -           
Forfeited   -    -                  
Outstanding at March 31, 2022   13,835,768   $0.53    4.49   $- 
Exercisable at March 31, 2022   4,538,479   $0.53    4.49   $- 

 

F-13

 

 

On March 10, 2022, the Company entered into a securities purchase agreement with certain institutional and accredited investors pursuant to which the investors agreed to purchase 18,594,571 shares of the Company’s common stock and warrants to purchase 9,297,289 shares of common stock in a private placement. The warrants have an exercise price of $0.2877 per share for a period of five years commencing six months from the closing date of March 11, 2022 (see Note 7).

 

On November 24, 2021, the Company granted John Bello, current Chairman, significant shareholder and former Interim Chief Executive Officer of Reed’s, who is a related party, a 5-year warrant to purchase 1,500,000 shares of the Company common stock with an exercise price of $0.46. The fair value of the warrants granted was determined to be $458 and was recorded as a prepaid financing costs. The unamortized balance of prepaid financing costs was $310 on December 31, 2021. During the three month ended March 31, 2022, the Company amortized $310 of prepaid financing costs to interest expense, leaving no remaining prepaid financing cost balance at March 31, 2022.

 

As of March 31, 2022, the outstanding and exercisable warrants have no aggregate intrinsic value. The aggregate intrinsic value was calculated as the difference between the closing market price as of March 31, 2022, which was $0.30, and the exercise price of the Company’s warrants to purchase common stock.

 

10. Related Party Activities

 

In 2018, the Company completed the sale of its Los Angeles manufacturing plant to California Custom Beverage, LLC (“CCB”), an entity owned by Christopher J. Reed, a related party, and CCB assumed the monthly payments on our lease obligation for the Los Angeles manufacturing plant. Our release from the obligation by the lessor, however, is dependent upon CCB’s deposit of $1,200 of security with the lessor. The deposit is secured by Mr. Reed’s pledge of common stock to the lessor and guaranteed personally by Mr. Reed and his wife. As of March 31, 2022, $800 has been deposited with the lessor and Mr. Reed has placed approximately 363,000 pledged shares valued at $109 that remain in escrow with the lessor.

 

Beginning in 2019, we are to receive a 5% royalty on CCB’s private label sales to existing customers and a 5% referral fee on CCB’s private label sales to referred customers for three years. The royalty agreement terminated December 31, 2021. During the three months ended March 31, 2022 and 2021, the Company recorded royalty revenue from CCB of $0 and $3, respectively.

 

At December 31, 2021, the Company had an aggregate receivable balance from CCB of $933. During the three months ended March 31, 2022, the Company advanced expenses of $8, leaving an aggregate receivable balance of $941 at March 31, 2022.

 

At March 31, 2022 and December 31, 2021, the Company had accounts payable due to CCB of $735 and $614, respectively.

 

Lindsay Martin, daughter of a director of the Company, is employed as Vice President of Marketing. Ms. Martin was paid approximately $46 and $87, respectively, for her services during the three months ended March 31, 2022 and 2021, respectively.

 

11. Subsequent Events

 

Subsequent to March 31, 2022, the Company issued 100,430 shares of common stock on the vesting of restricted shares.

 

On May 9, 2022, the Company entered into a note purchase agreement and agreed to issue $11,250 of secured convertible promissory notes (the “Notes”). The net proceeds from the issuance of the Notes, after deducting placement agent fees and other offering expenses, was approximately $10,013. The Notes will mature on May 9, 2025, bear interest at a rate of 10% per annum, and are secured by substantially all of the Company’s assets (including all of its intellectual property) and are subject to a collateral sharing agreement with ACS, the Company’s existing secured lender (see Note 5). The Notes also have an amortization feature beginning in August 2022, which, if elected by a majority of holders, would require the Company to make monthly payments of $200 of principal and interest in cash or in shares of common stock.

 

The initial conversion rate of the Notes is 4.1503 shares of the Company’s common stock per one dollar of principal converted, subject to customary anti-dilution adjustments. Upon conversion, holders of the Note are entitled to receive an interest make-whole payment, as defined, which is payable, at the Company’s election, in cash or in shares of common stock valued at a 10% discount to the 5-day volume-weighted average price. The Company’s ability to settle conversions and make amortization and interest make-whole payments using shares of the Company’s common stock is subject to certain limitations set forth in the Notes.

 

The Company entered into a registration rights agreement with the holders, pursuant to which the Company agreed to register for resale shares issuable under the Notes within 45 days of the closing of Notes. The Company is currently in the process of determining its accounting for the Notes.

 

F-14

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Cautionary Statement Regarding Forward-Looking Statements and Information

 

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and the related notes appearing elsewhere in this report.

 

In addition to our GAAP results, the following discussion includes Modified EBITDA as a supplemental measure of our performance. We present Modified EBITDA because we believe it assists investors and analysts in comparing our performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. In addition, we use Modified EBITDA in developing our internal budgets, forecasts, and strategic plan; in analyzing the effectiveness of our business strategies in evaluating potential acquisitions; making compensation decisions; and in communications with our board of directors concerning our financial performance. Modified EBITDA is not a recognized measurement under GAAP and should not be considered as an alternative to net income, income from operations or any other performance measure derived in accordance with GAAP, or as an alternative to cash flow from operating activities as a measure of liquidity. We define Modified EBITDA as net income (loss), plus interest expense, depreciation and amortization, stock-based compensation, changes in fair value of warrant expense, and one-time restructuring-related costs including employee severance and asset impairment.

 

The following discussion also includes the use of gross billing, a key performance indicator and metric. Gross billing represents invoiced amounts to distributors and retailers, excluding sales adjustments. Gross billing may include deductions from MSRP or “list price”, where applicable, and excludes promotional costs of generating such sales. Management utilizes gross billing to monitor operating performance of products and salespersons, which performance can be masked by the effect of promotional or other allowances. Management believes that the presentation of gross billing provides a useful measure of Reed’s operating performance.

 

Overview

 

During the first quarter of 2022, the Company continued to strengthen its supply chain, implement gross margin enhancement initiatives, drive efficiencies in transportation and warehouse costs and reduce operating expenses. In addition, it continues to build its innovation pipeline with sustained growth in Reed’s Real Ginger Ale and Reed’s Classic Mule. At the end of the quarter, the Company shipped its rebranded Virgil’s zero sugar line in 12 oz. sleek cans and produced its new line of hard ginger ale for its pending launch.

 

As noted above, the Company remains focused on driving sales growth and improving margin. The sales growth focus is on channel expansion, new product introduction and improved sales execution. The margin enhancement initiative is driven by co-packer upgrades, better leveraged purchasing and improved efficiency. Underpinning these initiatives is a focus on strategically reducing operating costs particularly delivery and handling expenses. During 2021, the Company experienced elevated transportation costs over the prior year and anticipates these costs to remain elevated for the balance of 2022. Plans have been implemented to mitigate the impact of these costs.

 

COVID-19 Considerations

 

During the period ended March 31, 2022, the COVID-19 pandemic continued to impact our operating results and the Company anticipates a residual effect for the balance of the year. In addition, the pandemic could cause reduced demand for our products if, for example, the pandemic results in a recessionary economic environment which negatively effects the consumers who purchase our products. Based on the recent increase in demand for our products, we believe that over the long term, there will continue to be strong demand for our products.

 

Through March 31, 2022, the Company was able to lower its freight costs despite a higher transportation market as the capacity in the freight market has not kept up with demand. The Company believes these challenges will continue throughout the year. In addition, the Company experienced increases in the pricing of several of its raw materials and delays in procuring several of these items. However, mitigation plans have been implemented to manage this risk. Additionally, the Company was negatively impacted by supply chain challenges impacting our ability to benefit from strong demand for, and increased sales of our product. The disruption caused by labor shortages, significant raw material cost inflation, logistics issues and increased freight costs, and ongoing port congestion, resulted in suppressed margins and net income. The Company anticipates a continued impact throughout 2022.

 

1

 

 

Our ability to operate without significant incremental negative operational impact from the COVID-19 pandemic will in part depend on our ability to protect our employees and protect our supply chain. The Company has endeavored to follow the recommended actions of government and health authorities to protect our employees. Since the inception of the COVID-19 pandemic and through March 31, 2022, we maintained the consistency of our operations during the onset of the COVID-19 pandemic. We will continue to innovate in managing our business, coordinating with our employees and suppliers to do our part in the infection prevention and remain flexible in responding to our customers and suppliers. However, the uncertainty resulting from the pandemic could result in an unforeseen disruption to our workforce and supply chain (for example an inability of a key supplier or transportation supplier to source and transport materials) that could negatively impact our operations.

 

Through March 31, 2022, we continued to generate cash flows to meet our short-term liquidity needs, and we expected to maintain access to the capital markets. We did not observe any material impairments of our assets or a significant change in the fair value of our assets due to the COVID-19 pandemic.

 

Results of Operations – Three Months Ended March 31, 2022, as compared to March 31, 2021

 

The following table sets forth key statistics for the three months ended March 31, 2022 and 2021, respectively, in thousands.

 

   Three Months Ended
March 31,		   Pct. 
   2022   2021   Change 
Gross billing (A)  $13,636   $13,281    3%
Less: Promotional and other allowances (B)   1,454    1,135    28%
Net sales  $12,182   $12,146    0%
                
Cost of goods sold   9,250    8,293    12%
% of Gross billing   68%   62%     
% of Net sales   76%   68%     
Gross profit  $2,932   $3,853    -24%
% of Net sales   24%   32%     
                
Expenses               
Delivery and handling  $2,812   $3,286    -14%
% of Net sales   23%   27%     
Dollar per case ($)  $3.90   $4.43      
Selling and marketing   2,178    2,215    -2%
% of Net sales   18%   18%     
General and administrative   2,121    2,603    -19%
% of Net sales   17%   21%     
Total operating expenses   7,111    8,104    -12%
                
Loss from operations  $(4,179)  $(4,251)   0%
                
Interest expense and other expense  $(801)  $(256)   213%
                
Net loss  $(4,980)  $(4,507)   10%
                
Loss per share – basic and diluted  $(0.05)  $(0.05)   -2%
                
Weighted average shares outstanding - basic & diluted   97,377,408    86,631,304    12%

 

(A) We define gross billing as the total sales for the Company unadjusted for costs related to generating those sales. Management utilizes gross billing as an indicator of and to monitor operating performance of products and salespersons before the effect of any promotional or other allowances, which are determined in accordance with GAAP, and can mask certain performance issues. We believe that the presentation of gross billing provides a useful measure of our operating performance. Additionally, gross billing may not be comparable to similarly titled measures used by other companies, as gross billing has been defined by our internal reporting practices.

 

2

 

 

(B) We define promotional and other allowances as costs deducted from gross billing which are associated with generating those sales. Management utilizes promotional and other allowances as an indicator of and to monitor operating performance of products, salespersons, and customer agreements. We believe that the presentation of promotional and other allowances provides a useful measure of our operating performance. The presentation of promotional and other allowances facilitates an evaluation of their impact on the determination of net sales and the spending levels incurred or correlated with such sales. The expenditures described in this line item are determined in accordance with GAAP and meet GAAP requirements, the disclosure thereof does not conform to GAAP presentation requirements. Additionally, our definition of promotional and other allowances may not be comparable to similar items presented by other companies. Promotional and other allowances primarily include consideration given to the Company’s distributors or retail customers including, but not limited to the following: (i) reimbursements given to the Company’s distributors for agreed portions of their promotional spend with retailers, including slotting, shelf space allowances and other fees for both new and existing products; (ii) the Company’s agreed share of fees given to distributors and/or directly to retailers for in-store marketing and promotional activities; (iii) the Company’s agreed share of slotting, shelf space allowances and other fees given directly to retailers; (iv) incentives given to the Company’s distributors and/or retailers for achieving or exceeding certain predetermined sales goals; and (v) discounted or free products. Promotional and other allowances constitute a material portion of our marketing activities. The Company’s promotional allowance programs with its numerous distributors and/or retailers are executed through separate agreements in the ordinary course of business. These agreements generally provide for one or more of the arrangements described above and are of varying durations, ranging from one week to one year.

 

Sales, Cost of Sales, and Gross Margins

 

The following chart sets forth key statistics for the transition of the Company’s top line activity from the first quarter of 2021 through the first quarter of 2022.

 

      2022   2021   vs PY   Q1 Per Case 
      Q1   Q1   Q1   2022   2021   vs PY 
Cases:                           
   Reed’s   415    395    5%               
   Virgil’s   302    339    -11%               
   Total Core   717    734    -2%               
   Non Core   -    -    -                
   Candy   4    8    -46%               
   Total   721    742    -3%               
                                  
Gross Billing:                                 
   Core  $13,287   $12,955    3%  $18.5   $17.6    5%
   Non Core   75    33    127%   -    -    -%
   Candy   274    293    -6%   63.8    36.6    74%
   Total  $13,636   $13,281    3%   18.9    17.9    6%
                                  
Discounts:  Total  $(1,454)  $(1,135)   28%  $(2.0)  $(1.5)   32%
                                  
COGS:                                 
   Core  $(9,150)  $(8,122)   13%  $(12.8)  $(11.1)   15%
   Non Core   (13)   (6)   113%   -    -    - 
   Candy   (87)   (165)   -47%   (20.3)   (20.6)   -1%
   Total  $(9,250)  $(8,293)   12%  $(12.8)  $(11.2)   15%
                                  
Gross Margin:     $2,932   $3,853    -24%  $4.1   $5.2    -22%
as % Net Sales      24%   32%                    

 

3

 

 

Sales, Cost of Sales, and Gross Margins

 

As part of the Company’s ongoing initiative to simplify and streamline operations the Company has identified core products on which to place its strategic focus. These core products consist of Reed’s and Virgil’s branded beverages. Non-core products consist primarily of Wellness Shots, candy and slower selling discontinued Reed’s and Virgil’s SKUs.

 

Core beverage volume for the three months ended March 31, 2022, represents 99% of all beverage volume.

 

Core brand gross billing increased by 3% to $13,287 compared to $12,955 during the same period last year, driven by Reed’s volume growth of 5% offset by Virgil’s volume decline of 11%. The result is an increase in total gross billing of 3%, to $13,636 during the three months ended March 31, 2022, from $13,281 in the same period last year. Price on our core brands increased 5% to $18.54 per case.

 

Discounts as a percentage of gross sales increased to 11% from 9% in the same period last year. As a result, net sales revenue increased less than 1% in the three months ended March 31, 2022, to $12,182, compared to $12,146 in the same period last year.

 

Cost of Goods Sold

 

Cost of goods sold increased $957 during the three months ended March 31, 2022, as compared to the same period last year. As a percentage of net sales, cost of goods sold for the three months ended March 31, 2022, was 76% as compared to 68% for the same period last year.

 

The total cost of goods per case increased to $12.83 per case in the three months ended March 31, 2022, from $11.18 per case for the same period last year. The cost of goods sold per case on core brands was $12.77 during the year months ended March 31, 2022, compared to $11.07 for the same period last year.

 

Gross Margin

 

Gross margin decreased to 24% for the three months ended March 31, 2022, compared to 32% for the same period last year.

 

Operating Expenses

 

Delivery and Handling Expenses

 

Delivery and handling expenses consist of delivery costs to customers and warehousing costs incurred for handling our finished goods after production. Delivery and handling expenses decreased by $474 in the three months ended March 31, 2022, to $2,812 from $3,286 in the same period last year, driven by our efforts to mitigate inflationary costs. Delivery costs in the three months ended March 31, 2022, were 23% of net sales and $3.90 per case, compared to 27% of net sales and $4.43 per case during the same period last year.

 

Selling and Marketing Expenses

 

Marketing expenses consist of direct marketing, marketing labor, and marketing support costs. Selling expenses consist of all other selling-related expenses including personnel and contractor support. Total selling and marketing expenses were $2,178 during the three months ended March 31, 2022, compared to $2,215 during the same period last year. As a percentage of net sales, selling and marketing costs remained flat at 18% during the three months ended March 31, 2022, as compared to the same period last year.

 

General and Administrative Expenses

 

General and administrative expenses consist primarily of the cost of executive, administrative, and finance personnel, as well as professional fees. General and administrative expenses decreased in the three months ended March 31, 2022, to $2,121 from $2,603, a decrease of $482 over the same period last year. The decrease was driven by lower stock compensation and legal settlements.

 

4

 

 

Loss from Operations

 

The loss from operations was $4,179 for the three months ended March 31, 2022, as compared to a loss of $4,251 in the same period last year driven by decreased gross profit offset by decreases in operating expenses discussed above.

 

Interest and Other Expense

 

Interest and other expense for the three months ended March 31, 2022, consisted of $801 of interest expense. During the same period last year, interest and other expense consisted of $256 of interest expense.

 

Modified EBITDA

 

In addition to our GAAP results, we present Modified EBITDA as a supplemental measure of our performance. However, Modified EBITDA is not a recognized measurement under GAAP and should not be considered as an alternative to net income, income from operations or any other performance measure derived in accordance with GAAP, or as an alternative to cash flow from operating activities as a measure of liquidity. We define Modified EBITDA as net income (loss), plus interest expense, depreciation and amortization, stock-based compensation, changes in fair value of warrant expense, legal settlements, and one-time restructuring-related costs including employee severance and asset impairment.

 

Management considers our core operating performance to be that which our managers can affect in any particular period through their management of the resources that affect our underlying revenue and profit generating operations during that period. Non-GAAP adjustments to our results prepared in accordance with GAAP are itemized below. You are encouraged to evaluate these adjustments and the reasons we consider them appropriate for supplemental analysis. In evaluating Modified EBITDA, you should be aware that in the future we may incur expenses that are the same as or similar to some of the adjustments in this presentation. Our presentation of Modified EBITDA should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items.

 

Set forth below is a reconciliation of net loss to Modified EBITDA for the three months ended March 31, 2022 and 2021 (unaudited; in thousands):

 

  

Three Months Ended

March 31

 
   2022   2021 
Net loss  $(4,980)  $(4,507)
           
Modified EBITDA adjustments:          
Depreciation and amortization   52    56 
Interest expense   801    256 
Stock option and other noncash compensation   291    398 
Legal settlements   -    353 
Total EBITDA adjustments  $1,144   $1,063 
           
Modified EBITDA  $(3,836)  $(3,444)

 

We present Modified EBITDA because we believe it assists investors and analysts in comparing our performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. In addition, we use Modified EBITDA in developing our internal budgets, forecasts and strategic plan; in analyzing the effectiveness of our business strategies in evaluating potential acquisitions; making compensation decisions; and in communications with our board of directors concerning our financial performance. Modified EBITDA has limitations as an analytical tool, which includes, among others, the following:

 

  ● Modified EBITDA does not reflect our cash expenditures, or future requirements, for capital expenditures or contractual commitments;
     
  ● Modified EBITDA does not reflect changes in, or cash requirements for, our working capital needs;
     
  ● Modified EBITDA does not reflect future interest expense, or the cash requirements necessary to service interest or principal payments, on our debts; and
     
  ● Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and Modified EBITDA does not reflect any cash requirements for such replacements.

 

5

 

 

Liquidity and Capital Resources

 

The accompanying financial statements have been prepared under the assumption that the Company will continue as a going concern. Such assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business.

 

For the three months ended March 31, 2022, the Company recorded a net loss of $4,980 and used cash in operations of $2,207. As of March 31, 2022, we had a cash balance of $122, with no current availability, and $5,100 of additional borrowing capacity, a stockholder’s equity of $4,616 and a working capital of $3,402, compared to a cash balance of $49 with borrowing capacity of $109, stockholders’ equity of $4,203 and a working capital of $2,981 at December 31, 2021. Notwithstanding the net loss for the three months ended March 31, 2022, management projects adequate cash from operations and available line of credit to ensure continuation of the Company as a going concern for at least one year from the date of this quarterly report.

 

Historically, we have financed our operations through public and private sales of common stock, issuance of preferred and common stock, convertible debt instruments, term loans and credit lines from financial institutions, and cash generated from operations. We have taken decisive action to improve our margins, including fully outsourcing our manufacturing process, streamlining our product portfolio, negotiating improved vendor contracts and restructuring our selling prices.

 

Critical Accounting Policies and Estimates

 

The preparation of the Company’s financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions used in estimates for reserves of uncollectible accounts, inventory obsolescence, depreciable lives of property and equipment, analysis of impairments of recorded long-term tangible and intangible assets, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services. There were no changes to our critical accounting policies described in the consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, that impacted our condensed consolidated financial statements and related notes included herein.

 

Recent Accounting Pronouncements

 

See Note 2 of the Notes to Condensed Financial Statements for a discussion of recent accounting pronouncements.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

A smaller reporting company is not required to provide the information required by this Item.

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

Under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, we conducted an evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective as of March 31, 2022, to provide reasonable assurance that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.

 

6

 

 

Changes in Internal Control Over Financial Reporting

 

There have been no changes in the Company’s internal control over financial reporting during the three months ended March 31, 2022 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings

 

We are subject to various legal proceedings from time to time in the ordinary course of business, none of which are required to be disclosed under this Item 1.

 

Item 1A. Risk Factors

 

In addition to other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the risk factors discussed in Part I, Item 1A of our Annual Report on Form 10-K (our Form 10-K) for the year ended December 31, 2021 and any subsequent filings with the Securities and Exchange Commission (SEC) made prior to the date hereof, which could materially affect our business, financial condition, results of operations or future results. These risks and uncertainties discussed in our Form 10-K and in any subsequent filings with the SEC made prior to the date hereof are not the only ones facing our business. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may materially adversely affect our business, cash flows, financial condition and/or results of operations. Please also read the Cautionary Notice Regarding Forward-Looking Statements and Information of this Quarterly Report on Form 10-Q.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None that have not been previously disclosed in a Current Report on Form 8-K.

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

None.

 

7

 

 

Item 6. Exhibits

 

Exhibit       Filed   Incorporated by Reference
No.   Exhibit Title   Herewith   Form   Exhibit   File No.   Date Filed
3(i)   Certificate of Incorporation of Reed’s, Inc., as amended       10-K   3(i)   001-32501   3/15/2022
3(ii)   Amended and Restated Bylaws of Reed’s, Inc.       10-KA   3.8   001-32501   4/08/2020
4.1   Form of Warrant issued to purchasers on March 11, 2022       8-K   4.1   001-32501   3/10/2022
4.2   Form of Warrant issued to Union Square Partners LP dated March 11, 2022       8-K   4.1   001-32501   3/21/2022
10.1   Form of Securities Purchase Agreement dated March 10, 2022 between Reed’s, Inc. and purchasers.       8-K   10.1   000-32501   3/10/2022
10.2   Form of Registration Rights Agreement dated March 10, 2022 between Reed’s, Inc. and purchasers       8-K   10.2   000-32501   3/10/2022
10.3   Rosenthal & Rosenthal, Inc. Partial Release of Pledge Agreement dated March 17, 2022       10-K   10.30   000-32501   3/15/2022
10.4   Ledgered ABL Agreement by and between Reed’s, Inc. and Alterna Capital Solutions, LLC dated March 28, 2022       10-K   10.31   000-32501   3/15/2022
31.1   Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002   X                
31.2   Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002   X                
32.1   Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002   X                
32.2   Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002   X                
101.INS   Inline XBRL Instance Document   X                
101.SCH   Inline XBRL Taxonomy Extension Schema Document   X                
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document   X                
101.DEF   Inline XBRL Taxonomy Extension Label Linkbase Document   X                
101.LAB   Inline XBRL Taxonomy Extension Presentation Linkbase Document   X                
101.PRE   Inline XBRL Taxonomy Extension Label Linkbase Document   X                
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)                    

 

In accordance with SEC Release 33-8238, Exhibits 32.1 and 32.2 are being furnished and not filed.

 

Furnished herewith, XBRL (Extensive Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

 

8

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

Reed’s, Inc.

(Registrant)

   
Date: May 16, 2022 /s/ Norman E. Snyder, Jr.
  Norman E. Snyder, Jr.
  Chief Executive Officer
  (Principal Executive Officer)
   
Date: May 16, 2022 /s/ Thomas J. Spisak
  Thomas J. Spisak
  Chief Financial Officer
  (Principal Financial Officer)

 

9

 

Reeds (NASDAQ:REED)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Reeds Charts.
Reeds (NASDAQ:REED)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Reeds Charts.